Lit­tle Capri­cor hits the brakes on a stem cell tri­al for Duchenne MD fol­low­ing an al­ler­gic re­ac­tion

The pen­ny stock play­er Capri­cor Ther­a­peu­tics $CAPR has stum­bled in­to an­oth­er pit­fall.

The biotech not­ed that it has vol­un­tar­i­ly halt­ed a clin­i­cal tri­al …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.